Akebia Announces Swissmedic Approval Of Vafseo
Portfolio Pulse from Happy Mohamed
Akebia Therapeutics (NASDAQ: AKBA) has received Swissmedic marketing authorization for Vafseo (vadadustat), a treatment for anemia associated with chronic kidney disease in adults on dialysis. The approval is based on data from a comprehensive development program, and the drug is now approved in 34 countries.
June 20, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics receives Swissmedic approval for Vafseo, a treatment for anemia in chronic kidney disease patients on dialysis, now approved in 34 countries.
The Swissmedic approval of Vafseo expands the market reach for Akebia Therapeutics, as the drug is now approved in 34 countries. This is likely to have a positive impact on the company's stock price in the short term, as it demonstrates the potential for increased revenue from the drug's sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100